Eli Lilly (LLY +0.5%) ups its FY net EPS forecast to $3.72-$3.82 to reflect income from the...

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

Eli Lilly (LLY +0.5%) ups its FY net EPS forecast to $3.72-$3.82 to reflect income from the early payment of $1.26B in revenue share from Amylin Pharmaceuticals - which has just been bought by Bristol-Myers Squibb - in connection with exenatide, a treatment for diabetes. Eli Lilly keeps its adjusted EPS unchanged at $3.30-$3.40 vs. forecasts of $3.37. (PR)